Elanco revenue hits $1.37B in strong quarterly showing

• Elanco’s second-quarter revenue increased 10% to $1.368 billion, with Pet Health and Farm Animal sales both growing.
• Adjusted EBITDA rose 21% to $288 million, while adjusted EPS increased 31% to $0.34.
• Elanco raised its full-year revenue, earnings and adjusted EBITDA guidance and improved its leverage target.

Elanco Animal Health (NYSE:ELAN) reported second-quarter revenue of $1.368 billion, up 10%, as Pet Health and Farm Animal sales increased.

Revenue rose from $1.241 billion, while adjusted EPS increased 31% to $0.34 and adjusted EBITDA climbed 21% to $288 million.

Net income reached $54 million, operating cash flow rose to $277 million and the net leverage ratio improved to 3.1 times adjusted EBITDA.

Elanco raised 2026 revenue guidance to $5.09–$5.14 billion.

Pet Health revenue increased 12% to $718 million, while Farm Animal revenue rose 9% to $633 million as global ruminant demand grew.

The company raised its innovation revenue target to $1.25 billion and now expects year-end net leverage of approximately 3.0 times adjusted EBITDA.